Industry News
AMD patients are reading letters again as PRIMA lands its CE mark in Europe
On Wednesday 22 July 2026, Science Corporation announced the European commercial launch of PRIMA, a two-millimetre subretinal photovoltaic chip that restores functional central vision in patients blinded by geographic atrophy from age-related macular degeneration. The CE mark, granted by DEKRA under the EU Medical Device Regulation, covers 30 European countries. The first commercial implant is expected in Germany. PRIMA is the first CE-marked implant to restore, rather than merely slow, central vision loss in AMD, and the FDA has granted it Humanitarian Use Device designation on the same day. Max Hodak's four-year-old company inherited the technology from Pixium Vision after the French developer's 2024 collapse.